References
- O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891–1904.
- Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066–1073.
- Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245(4922):1059–1065.
- Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073–1080.
- Collie JT, Massie RJ, Jones OA, et al. Sixty-five years since the New York heat wave: advances in sweat testing for cystic fibrosis. Pediatr Pulmonol. 2014;49(2):106–117.
- Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992–2001.
- De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med. 2016;4(8):662–674.
- Marson FAL, Bertuzzo CS, Ribeiro JD. Classification of CFTR mutation classes. Lancet Respir Med. 2016;4(8):e37–e38.
- Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol Med. 2012;18(2):81–91.
- Balch WE, Roth DM, Hutt DM. Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol. 2011;3:2.
- Roth DM, Hutt DM, Tong J, et al. Modulation of the maladaptive stress response to manage diseases of protein folding. PLoS Biol. 2014;12(11):e1001998.
- Cystic Fibrosis Foundation Patient Registry: 2016 annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2017 cited 2018 May 1. Available from: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2016-Patient-Registry-Annual-Data-Report.pdf
- Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106(44):18825–18830.
- Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–1672.
- Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015;192(7):836–842.
- Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219–1225.
- De Boeck K, Munck A, Walker S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014;13(6):674–680.
- Moss RB, Flume PA, Elborn JS, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015;3(7):524–533.
- Van Goor F, Yu H, Burton B, et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014;13(1):29–36.
- Durmowicz AG, Lim R, Rogers H, et al. The U.S. Food and Drug Administration’s experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial. Ann Am Thorac Soc. 2018;15(1):1–2.
- Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011;108(46):18843–18848.
- Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(18):1783–1784.
- Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017;5(2):107–118.
- Elborn JS, Ramsey BW, Boyle MP, et al. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med. 2016;4(8):617–626.
- Taylor-Cousar JL, Jain M, Barto TL, et al. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. J Cyst Fibros. 2018;17(2):228–235.
- Hubert D, Chiron R, Camara B, et al. Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. J Cyst Fibros. 2017;16(3):388–391.
- Jennings MT, Dezube R, Paranjape S, et al. An observational study of outcomes and tolerances in patients with cystic fibrosis initiated on lumacaftor/ivacaftor. Ann Am Thorac Soc. 2017;14(11):1662–1666.
- Popowicz N, Wood J, Tai A, et al. Immediate effects of lumacaftor/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease. J Cyst Fibros. 2017;16(3):392–394.
- Robertson SM, Luo X, Dubey N, et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol. 2015;55(1):56–62.
- Jordan CL, Noah TL, Henry MM. Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis. Pediatr Pulmonol. 2016;51(S44):S61–S70.
- Rudashevskaya EL, Stockner T, Trauner M, et al. Pharmacological correction of misfolding of ABC proteins. Drug Discov Today Technol. 2014;12:e87–e94.
- Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest. 2005;115(9):2564–2571.
- Ren HY, Grove DE, De La Rosa O, et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell. 2013;24(19):3016–3024.
- Mijnders M, Kleizen B, Braakman I. Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis. Curr Opin Pharmacol. 2017;34:83–90.
- Van Goor F. Nonclinical profile of the CFTR corrector VX-661. Pediatr Pulmonol. 2016;51(S45):S194–S485.
- Donaldson SH, Pilewski JM, Griese M, et al. Tezacaftor/ivacaftor in subjects with cystic fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Am J Respir Crit Care Med. 2018;197(2):214–224.
- Symdeko [package insert]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2018 [cited 2018 May 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf.
- Sabers A. Pharmacokinetic interactions between contraceptives and antiepileptic drugs. Seizure. 2008;17(2):141–144.
- Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med. 2017;377(21):2024–2035.
- Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med. 2017;377(21):2013–2023.
- Vertex provides update on ongoing phase 3 program for VX-661 in combination with ivacaftor for the treatment of cystic fibrosis; 2016 [cited 2018 May 1]. Available from: https://investors.vrtx.com/news-releases/news-release-details/vertex-provides-update-ongoing-phase-3-program-vx-661
- Vertex reports third-quarter 2017 financial results; 2017 [cited 2018 May 1]. Available from: https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2017-financial-results
- Flume PA, Owen CA, Brown CD, et al. Long-term safety and efficacy of tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR or heterozygous for F508del and a residual function mutation: first interim analysis results of a phase 3, open-label, rollover study. Am J Respir Crit Care Med. 2018;197:A7807.
- Vertex initiates phase 3 study of VX-659, tezacaftor and ivacaftor as a triple combination regimen for people with cystic fibrosis who have two copies of the F508del mutation; 2018 [cited 2018 May 1]. Available from: https://investors.vrtx.com/news-releases/news-release-details/vertex-initiates-phase-3-study-vx-659-tezacaftor-and-ivacaftor
- Vertex selects two next-generation correctors, VX-659 and VX-445, to advance into phase 3 development as part of two different triple combination regimens for people with cystic fibrosis; 2018 [cited 2018 May 1]. Available from: https://investors.vrtx.com/news-releases/news-release-details/vertex-selects-two-next-generation-correctors-vx-659-and-vx-445
- Vertex initiates phase 3 studies of VX-445, tezacaftor and ivacaftor as a triple combination regimen for people with cystic fibrosis; 2018 [cited 2018 May 1]. Available from: https://www.vrtx.com/story/vertex-initiates-phase-3-vx-445-triple-combination-studies
- Proteostasis therapeutics announces FDA grants breakthrough therapy designation for PTI-428 in cystic fibrosis; 2018 [cited 2018 May 1]. Available from: http://ir.proteostasis.com/news-releases/news-release-details/proteostasis-therapeutics-announces-fda-grants-breakthrough